New CAR-T therapy offers hope for lymphoma patients after first-line treatment fails
NCT ID NCT04316624
First seen Feb 16, 2026 · Last updated May 12, 2026 · Updated 12 times
Summary
This early-stage study tested a new type of CAR-T cell therapy (C-CAR066) in 7 adults with diffuse large B-cell lymphoma whose cancer returned or didn't respond after a prior CAR-T treatment. The therapy targets a protein called CD20 on cancer cells. The main goals were to check safety and see if the treatment could shrink tumors. Because patients may need ongoing monitoring or additional treatments, this is considered disease control rather than a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.